Bing Xia

5PUBLICATIONS

35CO-AUTHORS

Molecular targetsLiquid biopsiesTumour immunologyChemical and thermal processes in energy and combustionCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (5)

Sort by Publication Date:

|Jul 10, 2026

Oncogenic EGFR rewires STING-TBK1 signalosomes to license DNA damage tolerance in NSCLC.

|Jan 06, 2026

Optimized patient-derived lung cancer organoids recapitulating the immune landscape for precision therapy evaluation.

Huayang Xing, Rui Liu, Yidan Chen

|May 16, 2025

Phase I/II Study of Tifcemalimab, an Anti-B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.

Ying Cheng, Jie Wang, Yan Yu

|Feb 28, 2024

IRF3 activates RB to authorize cGAS-STING-induced senescence and mitigate liver fibrosis.

Qirou Wu, Xiaohong Leng, Qian Zhang

|Feb 02, 2022

Postoperative radiotherapy for patients with completely resected stage IIIA-N2 non-small cell lung cancer: opt-in or opt-out.

Lucheng Zhu, Bing Xia, Shenglin Ma

Pageof 1

Frequent Collaborators

Pinglong Xu

Chen Mei

Li Shen

Xin-Hua Feng

Qirou Wu

Xiaohong Leng

Qian Zhang

Ruyuan Zhou

Dan Zhang

Shasha Chen

Frequent Collaborators

Pinglong Xu

Chen Mei

Li Shen

Xin-Hua Feng